Emerging Stock Report Initiates Independent Research Coverage On Imaging Diagnostic Systems, Inc.

Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Imaging Diagnostic Systems, Inc. (OTCBB:IMDS). Emerging Stock Report is currently offering a complimentary trial subscription. To view our research go to: http://www.emergingstockreport.com.

About ESR:

Emerging Stock Report is a leading provider of independent investment research for North American companies. Our services include research analysis on emerging growth companies, sector specific research, real-time news and financial data, market commentary and the ESR newsletter. Emerging Stock Report's staff of investment professionals are dedicated to providing the tools and resources necessary to help make important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, visit http://www.emergingstockreport.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at http://emergingstockreport.com/register.php

About Imaging Diagnostic Systems, Inc. (OTCBB:IMDS)

Imaging Diagnostic Systems, Inc.(OTCBB:IMDS) has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM(R) system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

The Company is currently engaged in collecting clinical data to support the Premarket approval application for marketing clearance in the U.S. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States.

ESR Disclosure:

Emerging Stock Report is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Emerging Stock Report has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, http://www.EmergingStockReport.com, for complete risks and disclosures.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Emerging Stock Report

CONTACT:  Emerging Stock Report
Dylan Anderson
206 905 9680
info@emergingstockreport.com

Related terms: advisor, breast cancer, clinical, computer, connecticut, federal, investment, law, market, marketing, research, securities, subscription, technology, trial, united states, web